

URINARY INCONTINENCE

1

OBJECTIVES

- ▶ Understand the demographics and types of urinary incontinence
- ▶ Report anatomical changes in the urinary system with age
- ▶ Describe the evaluation and treatment of urinary incontinence.

2

TOPICS COVERED

Demographics of Incontinence

Risk Factors and Associated Comorbid Conditions

Pathophysiology

Evaluation

Treatment

Nursing Homes, catheters and catheter Care

3

PREVALENCE OF UI

- Approximately 1:4 community-dwelling older adults
- 2/3 of long-term-care resident
- Increases with age
- Affects women than men (2:1) until age 80 (then 1:1)

4

Impact of urinary incontinence

- ❖ Dermatitis, cellulitis, pressure ulcers, UTIs
- ❖ Sleep deprivation, falls with fractures, sexual dysfunction
- ❖ Depression, social withdrawal, impaired quality of life

5

Risk factors for Urinary Incontinence

- Obesity
- Functional impairment
- Dementia
- Medications
- Diabetes
- Environmental barriers to toilet access

6

Comorbidities that cause or worsen incontinence

- Affective disorders
- Alcoholism
- Chronic cough
- CHF
- Constipation
- DJD
- Delirium
- Dementia
- Diabetes
- Hypercalcemia
- Mobility impairment
- Multiple sclerosis
- NPH
- Parkinson disease
- Psychosis
- Rheumatoid arthritis
- Sleep apnea
- Spinal cord injury/ stenosis
- Stroke
- Vitamin B₁₂ deficiency

7

Medications that can cause or worsen incontinence

- Alcohol
- α -Adrenergic agonists (M)
- α -Adrenergic blockers (W)
- ACE inhibitors
- Anticholinergics
- Antipsychotics
- Calcium channel blockers
- Cholinesterase inhibitors
- Estrogen (oral)
- GABAergic agents
- Loop diuretics
- Narcotic analgesics
- NSAIDs
- Sedative hypnotics
- Thiazolidinediones
- Tricyclic antidepressants

8

Age changes in the urinary tract

- Decreased bladder contractility
- Increased uninhibited bladder contractions
- Diurnal urine output shifted later in the day
- Sphincteric striated muscle attenuation
- Decreased bladder capacity
- (Modest) Increased postvoid residual (PVR)
- Decreased urethral closure pressure, increased vaginal mucosal atrophy (women)
- Benign prostatic hyperplasia and prostate hypertrophy (men)

9

What causes incontinence

- Urge incontinence = detrusor overactivity (uninhibited bladder contractions)
- Stress incontinence = impaired urethral sphincter support and/or closure
- Mixed incontinence = features of stress and urge
- Overflow incontinence = bladder outlet obstruction and/or detrusor underactivity

10

Urge incontinence

Detrusor overactivity:

- Age-related
- Idiopathic
- Lesion in central inhibitory pathways (eg, stroke, cervical stenosis)
- Bladder outlet obstruction or bladder irritation (eg, stones, infection, tumor)

11

Stress incontinence

Leakage due to:

- **Damage to pelvic floor supports** (levator ani, connective tissues)
 - Failure to adequately compress the urethra when intra-abdominal pressure increases
- **Sphincter failure**
 - Surgical damage or severe atrophy
 - Subsacral spinal cord injury rarely

12

Stress incontinence

- Cough can trigger an uninhibited detrusor contraction
 - Leakage occurs after and not coincident with the cough, is large in volume, and is difficult to stop
- Often coexists with urge UI (mixed UI)

13

Impaired emptying

- From detrusor underactivity, bladder outlet obstruction, or both
- Outlet obstruction causes
 - Men: prostate hyperplasia
 - Women: urethral scarring or large cystocele/prolapse that kinks urethra

14

Impaired bladder emptying

- Detrusor underactivity results from:
 - **Intrinsic bladder smooth muscle damage** (eg, ischemia, scarring, fibrosis)
 - **Peripheral neuropathy** (eg, diabetes, vitamin B₁₂ deficiency, alcoholism)
 - **Damage to spinal cord or spinal bladder efferent nerve** (eg, from disc herniation, spinal stenosis, tumors, or degenerative neurologic disease)

15

NOCTURIA

- **Nocturnal polyuria** (nocturnal output >33% of total 24-hour urine output)
 - Late day/evening fluids, especially with caffeine or alcohol
 - Pedal edema (eg, due to medications, venous stasis, heart failure)
 - Heart failure
 - Obstructive sleep apnea

16

Nocturia

- **Sleep disturbance**
 - Obstructive sleep apnea
 - Medications
 - Cardiac or pulmonary disease
 - Pain
 - Restless leg syndrome
 - Depression
 - Sleep partner

17

Nocturia

Lower urinary tract

- Detrusor over activity
- Benign prostatic hyperplasia
- Impaired bladder emptying

18

Assessment of urinary incontinence

- **Screen:** all patients, they don't report
- **History:** include what matters and quality of life
- **Physical examination:** include cardiovascular, abdominal, musculoskeletal, neurologic, & genitourinary exams
- **Testing:** urinalysis
- **Optional:** PVR, urodynamics, cytology, other lab tests

19

Screening

- Ask:
 - Do you have any problems with bladder control?
 - Do you have problems making it to the bathroom on time?
 - Do you ever leak urine?
- **If positive, ask questions to determine the type of incontinence**

20

CLASSIFICATION QUESTIONS TO FOLLOW UP POSITIVE SCREEN

Do you leak urine mostly:

- When you are performing some physical activity, such as coughing, sneezing, lifting, or exercising? (**stress UI**)
- When you have the urge or feeling that you need to empty your bladder but cannot get to the toilet fast enough? (**urge UI**)

21

Do you leak urine mostly...

- With both physical activity and a sense of urgency? (**mixed UI**)
- Without physical activity and without sense of urgency? (**other**)

22

ASSESSMENT: HISTORY

- **Should include:** onset, frequency, volume, timing, exacerbating and ameliorating factors, other LUT symptoms, amount/types of fluid intake, success or failure of past treatment(s), current management
- **Red flag symptoms:** abrupt onset, pelvic pain, hematuria (could herald neurologic disease or cancer—prompt evaluation and referral required)

23

Assessment

- **Review:** medical conditions and their status, medications, functional status, access to toilets
- **Ask patients and/or caregivers about incontinence associated bother and impact on quality of life**


24

Physical exam

- **General:** cognitive and functional status, sleep apnea screening if nocturia
- **Abdominal:** palpation / percussion, bladder scan
- **Neurologic:** tests for integrity of the sacral cord with sacral reflexes:
 - Perineal sensation
 - Anal wink
 - Bulbocavernosus reflex

25

Physical: Testing Sacral Reflexes



26

Physical exam

- **Genitourinary:**
 - Digital rectal exam to check for masses, fecal loading
 - **Men:** prostate nodules/firmness, masses
 - if uncircumcised, check for phimosis, paraphimosis, balanitis
 - **Women:** labial and vaginal lesions, marked pelvic organ prolapse

27

Physical exam: Clinical Stress Test

- Full bladder is full
- Patient relaxes perineum and buttocks, examiner positioned to observe or catch any leakage with single vigorous cough

28

Laboratory Tests

Only recommended test for all patients:
urinalysis, to check for hematuria and glycosuria in diabetics

- Diagnosis of UTI requires additional signs and symptoms
- Do not treat asymptomatic bacteriuria

29

TESTING: Bladder Diary

- Frequency, timing, and circumstances
- record the time and volume of all continent voids and UI episodes for 2–3 days, including day and evening

30

TESTING: Postvoid Residual (PVR)

- Consider PVR measurement in those with:
 - Prior urinary retention
 - Longstanding diabetes
 - Recurrent urinary tract infections
 - Severe constipation
 - Complex neurologic disease
 - Higher than routine risk for prostate enlargement (men)
 - Marked pelvic organ prolapse

31

TESTING: Urodynamic Testing

- **Routine urodynamic testing is not necessary or desirable**
- **Consider only if:**
 - The cause of UI is unclear and knowing it would change management
 - Empiric treatment has failed and the patient would consider invasive or surgical therapy

32

Management

- Stepped management strategy:



33

LIFESTYLE FACTORS

- Weight loss (young old)
- Non evidenced but sensible:
 - Avoid extreme fluid intake, caffeinated beverages, alcohol
 - Minimize evening intake in those with nocturia
 - Elevate feet one hour before bedtime
 - Quitting smoking

34

Behavioral therapy

- **Bladder training and pelvic muscle exercise (PME):** effective for urge, stress, and mixed UI
- **Prompted voiding:** cognitively-impaired patients with urge incontinence

35

Bladder training

- Urgency suppression using CNS and pelvic mechanisms
 - Be still, don't run to the bathroom
 - Do several pelvic muscle contractions
 - When urgency decreases, then go to the bathroom
- Success may take several weeks; reassure patient

36

Bladder training

- Frequent voluntary voiding to keep bladder volume low
 - Initial toileting frequency: About 2 hr, or use the shortest interval between voids from bladder diary if possible
 - Increase time between scheduled voids by ~30–60 minutes until reach a comfortable level balancing voiding frequency and continence

37

Bladder training for cognitively impaired

- Only prompted voiding is proven effective
- Caregiver:
 - Monitors the patient and encourages him or her to report any need to void
 - Prompts the patient to toilet on a regular schedule during the day (usually every 2–3 hours)
 - Leads the patient to the bathroom
 - Gives the patient positive feedback when he or she toilets
- Habit training and scheduled voiding are not effective

38

PELVIC MUSCLE EXERCISES

- Effective for urge, mixed, and stress UI
- Requires motivated patient & careful instruction,
 - Instruction books work
- **Perform an isolated pelvic muscle contraction**; avoid buttock, abdomen, thigh muscle contraction. Hold 6–8 seconds
- **Repeat the contraction 8–12 times (one set)**; relax the pelvis between each contraction
- **Complete 3 sets daily at least 3–4 times a week**; continue at least 15–20 weeks

39

Medications: antimuscarinic agents

- Moderately effective for urge, overactive bladder, and mixed urinary incontinence
- **Contraindicated in patients with narrow-angle glaucoma, impaired gastric emptying, or urinary retention**
- Work by increasing bladder capacity; they do not ablate uninhibited contractions
- Routine PVR monitoring is unnecessary

40

ANTIMUSCARINIC AGENTS

Agent	Dosing	Considerations
Oxybutynin IR	2.5–5 mg q6–12h	P450 interactions
Oxybutynin ER	5–20 mg/day	
Oxybutynin patch	3.9 mg/24 h, 2x/week	
Oxybutynin gel	3% gel or 10% sachet daily	
Tolterodine IR	1–2 mg q12h	P450 interactions; consider dose adjustment in renal impairment
Tolterodine ER	2–4 mg/day	
Tropium IR	20 mg q12h or q24h	Renal clearance; give once daily in pts with renal impairment; should be taken on empty stomach
Tropium ER	60 mg daily in AM	
Darifenacin	7.5–15 mg/day	P450 interactions
Solifenacin	5–10 mg/day	P450 interactions; consider dose adjustment in renal impairment
Fesoterodine	4–8 mg/day	P450 interactions; prodrug that is metabolized to tolterodine; consider dose adjustment in renal impairment

41

Medication side effects

- Dry mouth with increased risk of **caries and constipation**
- Class effect: **cognitive impairment**
- **Do not combine with cholinesterase inhibitors** because of lack of efficacy, risk of increased functional and possibly cognitive impairment

42

Mirabegron

- β_3 -adrenergic agonist that stimulates detrusor relaxation and increases bladder capacity
- Dosing: 25–50mg/d
- Similar moderate efficacy as antimuscarinics
- No cognitive issues
- May raise blood pressure
- Drug-drug interactions: digoxin, metoprolol, venlafaxine, desipramine, dextromethorphan

43

OTHER MEDICATIONS

- **Duloxetine** (off-label) decreases stress incontinence
- **Vaginal estrogen** — may decrease recurrent UTIs, insufficient evidence for improvement of incontinence
- **Do not use vasopressin for nocturia** (risk of hyponatremia in older adults)
- **Insufficient evidence** for propantheline, dicyclomine, imipramine, hyoscyamine, calcium channel blockers, NSAIDs, flavoxate

44

Procedures

- ▶ **Sacral nerve neuromodulation** has some effect for urge UI refractory to drug treatment and urinary retention (idiopathic and neurogenic)
- ▶ **Posterior tibial nerve stimulation** — less invasive form of neuromodulation with a response rate of 60–81% in small short-term trials
- ▶ **Intravesical injection of botulinum toxin** is effective for refractory urge UI
- ▶ **Pessaries** for women with stress or urge UI exacerbated by bladder or uterine prolapse

45

SURGERY

- Highest cure rates for stress UI in women
- Most common:
 - Colposuspension (Burch operation)
 - Slings (midurethral and bladder neck)
- Periurethral injection of a bulking agent for short term (≤ 1 year)
- Artificial sphincters for refractory stress incontinence from sphincter damage (eg, after radical prostatectomy)

46

SUMMARY

- Urinary incontinence is common
 - impaired quality of life, morbidity, and increased costs
- Age-related changes and common disorders increase risk of incontinence
- Evaluation is based on history, physical, and focused laboratory testing

47

SUMMARY

- Treatment is stepwise, starting with remediation of comorbid and lifestyle factors, progressing to behavioral therapy, medications, and, if necessary, surgery

48

CASE 1 (1 of 4)

- ▶ An 82-year-old man is seen for routine follow-up. He states that he is not sure he empties his bladder completely when he voids.
- ▶ He has had gradual onset of urgency with the need to void, and occasionally is incontinent on the way to the bathroom.
 - ▶ On average, he voids 8 times daily and twice overnight.
 - ▶ He occasionally experiences hesitancy when initiating a void, and the stream is interrupted and weak.
 - ▶ He describes post-void dribbling and staining on his undergarments.
- ▶ History: hypertension, hypercholesterolemia; he had a stroke 2 years ago, with no residual weakness.
- ▶ Medications: amlodipine, hydrochlorothiazide, rosuvastatin, aspirin

49

CASE 1

- ▶ Examination
 - ▶ BP 118/64 mmHg.
 - ▶ The suprapubic area is slightly tender and dull to percussion. Genitalia are normal.
 - ▶ The prostate is moderately enlarged and nontender, without nodularity or other abnormality.
 - ▶ Bladder ultrasonography after attempted void shows postvoid residual of 175 mL.
 - ▶ Urinalysis reveals no evidence of infection.
 - ▶ Creatinine level is 1.1 mg/dL.

50

CASE 1

Which one of the following is the most appropriate next step?

- A. Stop hydrochlorothiazide.
- B. Start oxybutynin.
- C. Start tamsulosin.
- D. Refer for urodynamic evaluation.

51

CASE 1

Which one of the following is the most appropriate next step?

- A. Stop hydrochlorothiazide.
- B. Start oxybutynin.
- C. **Start tamsulosin.**
- D. Refer for urodynamic evaluation.

52